Prevent cervical cancer by screening with reliable human papillomavirus detection and genotyping (pages 59–67)
Shichao Ge, Bo Gong, Xushan Cai, Xiaoer Yang, Xiaowei Gan, Xinghai Tong, Haichuan Li, Meijuan Zhu, Fengyun Yang, Hongrong Zhou and Guofan Hong
Article first published online: 5 JUL 2012 | DOI: 10.1002/cam4.9
The high-risk HC2 test correctly detected 388 (57.6%) of the 674 high-risk HPV isolates in clinical specimens, mislabeled 88 (46.8%) of the 188 low-risk HPV isolates as high-risk genotypes, and classified 180 (27.4%) of the 657 “true negative” samples as being infected by high-risk HPV. It was found to cross-react with 20 low-risk HPV genotypes. We conclude that nested PCR detection of HPV followed by short target DNA sequencing can be used for screening and genotyping to formulate a paradigm in clinical management of HPV-related disorders in a rapidly developing economy.